Ovarian Suppression in Premenopausal Hormone Receptor-Positive Breast Cancer
Higher-risk premenopausal women with hormone receptor-positive breast cancer should receive ovarian suppression added to endocrine therapy for 5 years, while lower-risk women should not receive ovarian suppression. 1
Risk-Stratified Approach to Ovarian Suppression
The decision to use ovarian suppression is based on recurrence risk, not patient preference or general considerations:
Who SHOULD Receive Ovarian Suppression:
- Stage II or III breast cancer where adjuvant chemotherapy would ordinarily be recommended → ovarian suppression MUST be added to endocrine therapy 1
- Stage I or II breast cancer at higher risk where chemotherapy might be considered → ovarian suppression may be offered 1
- Women who remain premenopausal after chemotherapy → particularly benefit from ovarian suppression 1
Who Should NOT Receive Ovarian Suppression:
- Stage I breast cancer not warranting chemotherapy → endocrine therapy alone without ovarian suppression 1
- Node-negative cancers ≤1 cm (T1a, T1b) → endocrine therapy alone without ovarian suppression 1
Methods of Ovarian Suppression
All three methods are acceptable and equivalent in efficacy 1:
GnRH agonists (most commonly used):
- Goserelin 3.6 mg every 4 weeks
- Leuprolide acetate 3.75 mg every 4 weeks
- Triptorelin 3.75 mg every 4 weeks
Surgical oophorectomy (permanent)
Ovarian irradiation (20 Gy in 10 fractions; permanent) 1
Important caveat: Approximately 10% of women receiving GnRH agonists fail to achieve adequate ovarian suppression 2. This is more common when combined with aromatase inhibitors (HR 12.83) 2. While routine estradiol monitoring is not mandated by guidelines, clinicians should maintain awareness of this phenomenon, particularly in patients on aromatase inhibitors.
Combination with Endocrine Therapy
Ovarian suppression may be administered with EITHER tamoxifen OR an aromatase inhibitor 1, 3. The choice depends on:
- Exemestane + ovarian suppression showed superior disease-free survival compared to tamoxifen + ovarian suppression (91.1% vs 87.3% at 5 years; HR 0.72) 4
- However, both combinations are acceptable standard options 1
- Consider individual toxicity profiles when choosing between tamoxifen and aromatase inhibitors 3
Duration of Treatment
5 years is the standard duration based on trial evidence 1. No comparative data exist for alternative durations, though extended treatment may be considered in selected high-risk patients 5.
Evidence Quality and Strength
This recommendation is based on intermediate quality evidence with moderate strength 1. The benefit was demonstrated in the SOFT and TEXT trials, which showed:
- Improved disease-free survival when ovarian suppression added to endocrine therapy (HR 0.83) 6
- Reduced mortality when ovarian suppression added to treatment (HR 0.86) 6
- Reduced contralateral breast cancer risk (HR 0.75) 6
The benefit was NOT observed when ovarian suppression was added to chemotherapy alone without tamoxifen (HR 0.95 for mortality) 6.
Critical Adverse Effects to Discuss
Ovarian suppression substantially increases:
- Hot flashes (RR 1.60) 6
- Menopausal symptoms including sweating, weight gain 1
- Sexual dysfunction including vaginal dryness and decreased libido 1
- Osteoporosis risk (RR 1.16) 6
- Quality of life impairment 1
These adverse effects contribute to reduced treatment adherence and must be weighed against the recurrence reduction benefit 1, 5.
Common Pitfalls
- Do not use ovarian suppression in ER-negative breast cancer - there is no role 1
- Do not assume chemotherapy-induced amenorrhea equals adequate suppression - women who remain premenopausal after chemotherapy are the ones who benefit most from ovarian suppression 1
- Do not use ovarian suppression as monotherapy - it must be combined with tamoxifen or an aromatase inhibitor 1
- Be aware of inadequate suppression with GnRH agonists, particularly when combined with aromatase inhibitors 2, 7